Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1468056

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1468056

RNA Interference Drug Delivery Market Report by Application, Technology, and Region 2024-2032

PUBLISHED:
PAGES: 135 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2999
PDF & Excel (5 User License)
USD 3999
PDF & Excel (Corporate License)
USD 4999

Add to Cart

The global RNA interference (RNAi) drug delivery market size reached US$ 84.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 410.3 Billion by 2032, exhibiting a growth rate (CAGR) of 18.7% during 2024-2032.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global RNA interference (RNAi) drug delivery market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and technology.

Breakup by Application:

Infectious Disease

Cardiology

Oncology

Neurology

Ophthalmology

Urology

Metabolic Disorders

Others

Breakup by Technology:

Nanoparticle Drug Delivery

Pulmonary Drug Delivery

Nucleic Acid Drug Delivery

Aptamer Drug Delivery

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc, and Sirnaomics Inc.

Key Questions Answered in This Report:

  • How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the technology?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
  • What is the degree of competition in the industry?
Product Code: SR112024A2758

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global RNA Interference (RNAi) Drug Delivery Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Infectious Disease
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cardiology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oncology
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Neurology
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Ophthalmology
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Urology
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Metabolic Disorders
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Nanoparticle Drug Delivery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Pulmonary Drug Delivery
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Nucleic Acid Drug Delivery
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Aptamer Drug Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Alnylam Pharmaceuticals Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Arrowhead Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 CureVac AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Dicerna Pharmaceuticals Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 Gradalis Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Ionis Pharmaceuticals Inc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Merck & Co. Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Moderna Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 Silence Therapeutics Plc
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
    • 13.3.11 Sirnaomics Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
Product Code: SR112024A2758

List of Figures

  • Figure 1: Global: RNA Interference (RNAi) Drug Delivery Market: Major Drivers and Challenges
  • Figure 2: Global: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Application (in %), 2023
  • Figure 4: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Region (in %), 2023
  • Figure 6: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: North America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: North America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: United States: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: United States: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Canada: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Canada: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: China: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: China: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Japan: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Japan: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: India: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: India: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: South Korea: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: South Korea: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Australia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Australia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Indonesia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Indonesia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Europe: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Europe: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Germany: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Germany: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: France: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: France: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: United Kingdom: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: United Kingdom: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Italy: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Italy: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Spain: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Spain: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Russia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Russia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Latin America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Latin America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Brazil: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Brazil: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Mexico: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Mexico: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: RNA Interference (RNAi) Drug Delivery Industry: SWOT Analysis
  • Figure 80: Global: RNA Interference (RNAi) Drug Delivery Industry: Value Chain Analysis
  • Figure 81: Global: RNA Interference (RNAi) Drug Delivery Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: RNA Interference (RNAi) Drug Delivery Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 3: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: RNA Interference (RNAi) Drug Delivery Market Structure
  • Table 6: Global: RNA Interference (RNAi) Drug Delivery Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!